THERAPY DOSSIER · th-c1269ab64715

Cyclophosphamide

Drug · DNA inhibitor (INHIBITOR; direct_interaction true, disease_efficacy true; mec_id 1846; prodrug, ATC L01AA01)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: DNA inhibitor (INHIBITOR; direct_interaction true, disease_efficacy true; mec_id 1846; prodrug, ATC L01AA01)
Target: CHEMBL2311221 (DNA)
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: 1959
Development stage: Not recorded
ChEMBL record: CHEMBL1200796 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Cytoxan; Endoxan; Neosar; Procytox; Cycloblastin; Revimmune; NSC-26271; B-518
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04231448 ↗PHASE3completed

Tucidinostat plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in MYC/BCL2 double-expressor DLBCL

Diffuse Large B-cell Lymphoma

Enrolment: 423 · Results not recorded

NCT05147493 ↗PHASE2unknown

Isatuximab with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed multiple myeloma with severe renal impairment (EAE116)

Multiple Myeloma · Renal Impairment

Enrolment: 51 · Results not recorded

NCT00526292 ↗PHASE2completed

HLA haploidentical natural killer cell infusion with cyclophosphamide/fludarabine conditioning for relapsed leukaemia

Leukemia · Myelodysplastic Syndromes

Enrolment: 12 · Results not recorded

NCT00061893 ↗PHASE2completed

Low-dose antiangiogenic chemotherapy including cyclophosphamide with standard multiagent chemotherapy in metastatic Ewing sarcoma

Sarcoma

Enrolment: 38 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23864800 ↗2013Mixed findings

The dose of cyclophosphamide for treating paraquat-induced rat lung injury.

RatChemical/toxinSprague-DawleyMalen = Control n=5; paraquat alone n=10; paraquat plus cyclophosph…Intraperitoneal1.5, 15 or 30 mg/kgImmediately after the paraquat injection

Model: Paraquat 35 mg/kg intraperitoneally in 1 ml saline, a dose giving about 60 per cent mortality; endpoint at 72 hours

Cyclophosphamide reduced micro-CT lesion extent and histological inflammation, with 15 mg/kg clearly better than 1.5 mg/kg and 30 mg/kg giving no further benefit, so 15 mg/kg was judged optimal. Antioxidant enzyme activity was restored and elevated serum TGF-beta1 reduced, although IL-6 and TNF-alp…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…